Craig Greven to Middle Aged
This is a "connection" page, showing publications Craig Greven has written about Middle Aged.
Connection Strength
0.152
-
Greven CM, Piccione K. Delayed visual loss after pars plana vitrectomy for retained lens fragments. Retina. 2004 Jun; 24(3):363-7.
Score: 0.023
-
Greven CM, Collins AS, Slusher MM, Weaver RG. Visual results, prognostic indicators, and posterior segment findings following surgery for cataract/lens subluxation-dislocation secondary to ocular contusion injuries. Retina. 2002 Oct; 22(5):575-80.
Score: 0.021
-
Singer MA, Miller DM, Gross JG, Greven CM, Kapik B, Bailey C, Ghanchi F, Kuppermann BD. Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I). Ophthalmic Surg Lasers Imaging Retina. 2018 09 01; 49(9):698-706.
Score: 0.016
-
Gower EW, Lovato JF, Ambrosius WT, Chew EY, Danis RP, Davis MD, Goff DC, Greven CM. Lack of Longitudinal Association Between Thiazolidinediones and Incidence and Progression of Diabetic Eye Disease: The ACCORD Eye Study. Am J Ophthalmol. 2018 03; 187:138-147.
Score: 0.015
-
Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, Genuth S, Goff DC, Leiter LA, Ismail-Beigi F, Ambrosius WT. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014 Dec; 121(12):2443-51.
Score: 0.012
-
Mottl AK, Pajewski N, Fonseca V, Ismail-Beigi F, Chew E, Ambrosius WT, Greven C, Schubart U, Buse J. The degree of retinopathy is equally predictive for renal and macrovascular outcomes in the ACCORD Trial. J Diabetes Complications. 2014 Nov-Dec; 28(6):874-9.
Score: 0.012
-
Casanova R, Saldana S, Chew EY, Danis RP, Greven CM, Ambrosius WT. Application of random forests methods to diabetic retinopathy classification analyses. PLoS One. 2014; 9(6):e98587.
Score: 0.012
-
van der Vaart R, Greven C, Manning R, Haines N, Kurup SK. Unilateral solitary choroidal granuloma as presenting sign of secondary syphilis. Graefes Arch Clin Exp Ophthalmol. 2011 Oct; 249(10):1575-7.
Score: 0.009
-
Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010 Jul 15; 363(3):233-44.
Score: 0.009
-
Ambrosius WT, Danis RP, Goff DC, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol. 2010 Mar; 128(3):312-8.
Score: 0.009
-
Saconn PA, Gee CJ, Greven CM, McCoy TP, Ekstrand KE, Greven KM. Alternative dose for choroidal melanoma treated with an iodine-125 radioactive plaque: a single-institution retrospective study. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):844-8.
Score: 0.009
-
Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007 Oct; 114(10):1860-7.
Score: 0.007